Buscar
IDEAYA Biosciences Inc
IDYAAñadir a la lista de seguimiento
28.210USD
-0.630-2.18%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
2.48BCap. mercado
PérdidaP/E TTM
Más Datos de IDEAYA Biosciences Inc Compañía
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Información de IDEAYA Biosciences Inc
Símbolo de cotizaciónIDYA
Nombre de la empresaIDEAYA Biosciences Inc
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHata (Yujiro S)
Número de empleados131
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 23
Dirección7000 Shoreline Ct, Suite 350
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504436209
Sitio Webhttps://www.ideayabio.com/
Símbolo de cotizaciónIDYA
Fecha de salida a bolsaMay 23, 2019
Director ejecutivoHata (Yujiro S)
Ejecutivos de IDEAYA Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
FY2025
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
218.71M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.97%
Janus Henderson Investors
8.18%
BlackRock Institutional Trust Company, N.A.
7.45%
Capital Research Global Investors
6.01%
State Street Investment Management (US)
4.71%
Otro
58.69%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.97%
Janus Henderson Investors
8.18%
BlackRock Institutional Trust Company, N.A.
7.45%
Capital Research Global Investors
6.01%
State Street Investment Management (US)
4.71%
Otro
58.69%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
49.16%
Investment Advisor/Hedge Fund
34.40%
Hedge Fund
18.19%
Venture Capital
4.64%
Research Firm
3.40%
Corporation
1.52%
Individual Investor
0.89%
Pension Fund
0.86%
Bank and Trust
0.43%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
518
97.55M
111.03%
-12.93M
2025Q4
494
96.98M
110.62%
-16.62M
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
13.15M
14.97%
+3.42K
+0.03%
Dec 31, 2025
Janus Henderson Investors
7.19M
8.18%
+758.12K
+11.79%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
6.54M
7.45%
+208.10K
+3.28%
Dec 31, 2025
Capital Research Global Investors
5.28M
6.01%
-1.27M
-19.43%
Dec 31, 2025
State Street Investment Management (US)
4.13M
4.71%
+893.71K
+27.58%
Dec 31, 2025
Baker Bros. Advisors LP
3.62M
4.12%
+343.38K
+10.48%
Dec 31, 2025
Logos Global Management LP
3.13M
3.56%
+875.00K
+38.89%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
3.40M
3.87%
-1.23M
-26.59%
Dec 31, 2025
Adage Capital Management, L.P.
2.80M
3.19%
-100.09K
-3.45%
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Tema Oncology ETF
3.49%
ALPS Medical Breakthroughs ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
0.83%
State Street SPDR S&P Biotech ETF
0.72%
First Trust Innovation Leaders ETF
0.7%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
ProShares Ultra Nasdaq Biotechnology
0.38%
Avantis US Small Cap Equity ETF
0.29%
Invesco Nasdaq Biotechnology ETF
0.27%
Ver más
Tema Oncology ETF
Proporción3.49%
ALPS Medical Breakthroughs ETF
Proporción1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.97%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción0.83%
State Street SPDR S&P Biotech ETF
Proporción0.72%
First Trust Innovation Leaders ETF
Proporción0.7%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.45%
ProShares Ultra Nasdaq Biotechnology
Proporción0.38%
Avantis US Small Cap Equity ETF
Proporción0.29%
Invesco Nasdaq Biotechnology ETF
Proporción0.27%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
